Physician profile
Lisa Avery
NPI 1699008409
$4,076.23
in general payments reported to CMS, 2019-2025
33 companies · $3,986 in 2025
The $3,986 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $89.98 · 2025: $3,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,877 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,876.53 |
| Education | $199.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $425.15 | 2024-2025 | Symbravo, Sunosi, Auvelity |
| Ucb, INC. | $393.33 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Pfizer INC. | $370.99 | 2025 | |
| Abbvie INC. | $366.74 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $218.37 | 2025 | Austedo Xr |
| Csl Behring | $192.31 | 2025 | Hizentra |
| Janssen Biotech, INC. | $180.72 | 2025 | |
| Emd Serono, INC. | $175.24 | 2025 | |
| Amgen INC. | $164.19 | 2025 | Uplizna |
| Harmony Biosciences LLC | $162.88 | 2025 | |
| Neurocrine Biosciences, INC. | $160.43 | 2025 | |
| Jazz Pharmaceuticals INC. | $139.49 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2025 | Wainua |
| Neurelis, INC. | $119.96 | 2024-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $104.60 | 2025 | Ultomiris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $85.12 | 2024-2025 | |
| Lundbeck LLC | $84.75 | 2025 | Vyepti |
| Acadia Pharmaceuticals INC | $84.67 | 2025 | Nuplazid |
| Lilly USA, LLC | $66.86 | 2025 | Kisunla |
| Impel Pharmaceuticals LLC | $59.35 | 2025 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $54.31 | 2025 | |
| Amneal Pharmaceuticals LLC | $45.67 | 2025 | Crexont |
| Inspire Medical Systems, INC. | $41.90 | 2025 | Inspire |
| Genentech USA, INC. | $39.15 | 2025 | Evrysdi, Ocrevus Zunovo |
| Merz Pharmaceuticals, LLC | $37.00 | 2025 | Xeomin, Inbrija |
| Springworks Therapeutics, INC. | $27.77 | 2025 | Gomekli |
| Genzyme Corporation | $25.01 | 2025 | |
| Scilex Pharmaceuticals INC. | $23.13 | 2025 | |
| Argenx US, INC. | $23.03 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Xeris Pharmaceuticals, INC. | $22.36 | 2025 | Keveyis |
| Collegium Pharmaceutical, INC. | $21.56 | 2025 | Belbuca |
| Kedrion Biopharma, INC. | $20.95 | 2025 | Koate, Kedrab, Gammaked |
| Takeda Pharmaceuticals U.S.A., INC. | $14.24 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Avery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.